Introduction and listing status of Vericigua tablets

Vericiguat is a soluble guanylate cyclase (sGC) stimulator, mainly used to treat chronic heart failure. This drug directly activates sGC and enhances the synthesis of cyclic guanosine monophosphate (cGMP), thereby improving vasodilation, reducing cardiac load, and improving cardiac pumping ability. Its primary indication is for patients with chronic heart failure with reduced ejection fraction (LVEF <45%), especially those who have recently been hospitalized for decompensated heart failure or are stable on intravenous therapy, to reduce the risk of hospitalization for heart failure or the need for emergency intravenous diuretic therapy.

The clinical efficacy of vericiguat has been verified in the "VICTORIA" phase III clinical trial. This study showed that compared with placebo, vericiguat can significantly reduce the risk of cardiovascular death and worsening of heart failure, showing good safety and tolerability. Therefore, this drug becomes an important new option for the treatment of chronic heart failure.
In terms of marketing, Vericiguat was approved for marketing by the U.S. Food and Drug Administration (FDA) for the first time in January 2021, and was subsequently approved in many countries such as Europe and Japan. In May 2022, China's National Medical Products Administration (NMPA) approved its use for the treatment of chronic heart failure with reduced ejection fraction, becoming the first approved sGC stimulator in China. On December 13, 2023, Vericiguat was officially included in the national medical insurance directory, which greatly reduced the financial burden on patients and enabled more heart failure patients to benefit from the treatment of this drug.
In general, as an innovative heart failure treatment drug, vericiguat has been rapidly promoted globally and has been recognized in the Chinese market, providing a new treatment method to improve the prognosis of heart failure patients.
Reference: https://www.gilead.com